---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-017185"
form_type: "8-K"
ticker: "RVPH"
cik: "0001742927"
company_name: "REVIVA PHARMACEUTICALS HOLDINGS, INC."
filed_at: "2025-05-15T23:59:59+00:00"
generated_at: "2026-05-21T05:20:55.128912+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Reviva Q1 2025 net loss $6.4M; cash $5.3M; OLE trial complete with 446 patients

## Summary
- Net loss $6.4M ($0.13/sh) vs $7.4M ($0.25/sh) in Q1 2024; cash & equivalents $5.3M as of Mar 31, 2025 down from $13.5M at Dec 31, 2024.
- Long-term OLE trial of brilaroxazine completed: 446 participants, 156 completed 12 months, 301 completed 6 months.
- Full OLE data (safety, efficacy, biomarkers) expected Q2 2025; registrational Phase 3 RECOVER-2 initiation expected mid-2025 subject to financing.
- NDA submission for brilaroxazine in schizophrenia targeted for Q4 2026; IND for psoriasis liposomal-gel formulation expected later in 2025.
- Company to present late-breaking poster on RECOVER 12-month OLE data at ASCP meeting on May 28, 2025.

## SEC filing metadata
- accession: 0001437749-25-017185
- form_type: 8-K
- ticker: RVPH
- cik: 0001742927
- company_name: REVIVA PHARMACEUTICALS HOLDINGS, INC.
- filed_at: 2025-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1742927/000143774925017185/0001437749-25-017185-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1742927/000143774925017185/rvph20250507_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-017185
- JSON: https://secwatch.observer/filing/0001437749-25-017185.json
- Plain text: https://secwatch.observer/filing/0001437749-25-017185.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.